510(k) device
Synergeyes Hybrid Contact Lenses - Daily Wear, Models A, M, Kc and Ps
Synergeyes, Inc. · Lens, Contact (Other Material) - Daily (HQD, Class II) · First FDA decision Sep 2, 2005, newest May 30, 2008Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
510(k) pathway
Device trials
2
Naming "Synergeyes Hybrid"
MAUDE reports
5
Brand "Synergeyes Hybrid", since 2015
PubMed studies
6
Mentioning "Synergeyes Hybrid"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Synergeyes Hybrid Contact Lenses - Daily Wear, Models A, M, Kc and Ps
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
K081034 · Decided May 30, 2008 · 49 days after receipt
Device type: Lens, Contact (Other Material) - Daily (HQD) · Ophthalmology
K080193 · Decided Mar 5, 2008 · 40 days after receipt
Device type: Lens, Contact (Other Material) - Daily (HQD) · Ophthalmology
K061120 · Decided Jun 22, 2006 · 62 days after receipt
Device type: Lens, Contact (Other Material) - Daily (HQD) · Ophthalmology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Synergeyes Hybrid", any status and sponsor, newest update first.
SynergEyes, Inc.Not on our public-company list
NCT01058629 · 125 participants (planned) · Start Aug 2009 · Primary completion Sep 2010
Device: SynergEyes A2 Hybrid Contact Lens · For: Refractive Errors; Astigmatism
Sites: Campbell, California; Carlsbad, California; Encino, California · 10 sites in all
SynergEyes, Inc.Not on our public-company list
NCT00804505 · 98 participants · Start Jun 2008 · Primary completion Nov 2008
Device: SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens; SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens · For: Corneal Disease; Hypersensitivity
Sites: San Diego, California; Sunnyvale, California; Andover, Massachusetts · 8 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Synergeyes Hybrid", and for the whole product code for context.
This brand
5 reports: 0 malfunction, 5 injury, 0 death
Whole product code HQD
37 reports: 3 malfunction, 34 injury, 0 death
Newest reports for this brand
3005087645-2015-00005 · Received Jul 1, 2015 · Event dated May 21, 2015
Device type: Lens, Contact (Other Material) - Daily (HQD)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Corneal Ulcer
3005087645-2015-00004 · Received May 12, 2015 · Event dated Mar 20, 2015
Device type: Lens, Contact (Other Material) - Daily (HQD)
Device problem as coded: Appropriate Device Problem Term/Code Not Available
Patient problem as coded: Corneal Ulcer
3005087645-2015-00003 · Received Apr 6, 2015 · Event dated Feb 6, 2015
Device type: Lens, Contact (Other Material) - Daily (HQD)
Device problem as coded: Use of Device Problem
Patient problem as coded: Corneal Ulcer
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Synergeyes Hybrid"[tiab]. The summary above synthesizes these.
- Oxygen demands with hybrid contact lenses.
Pilskalns B, Fink BA, Hill RM · Optom Vis Sci · 2007
- SynergEyes lenses for keratoconus.
Abdalla YF, Elsahn AF, Hammersmith KM, et al. · Cornea · 2010
- ClearKone-Synergeyes or rigid gas-permeable contact lens in keratoconic patients: a clinical decision.
Hashemi H, Shaygan N, Asgari S, et al. · Eye Contact Lens · 2014Comparative Study
- Bilateral Acanthamoeba keratitis in Synergeyes contact lens wear: clinical and confocal microscopy findings.
Lee WB, Gotay A · Eye Contact Lens · 2010Case Reports, Research Support, Non-U.S. Gov't
- A comparison of the visual acuity outcome between Clearkone and RGP lenses.
Hassani M, Jafarzadehpur E, Mirzajani A, et al. · J Curr Ophthalmol · 2018
- Severe epithelial edema in Clearkone SynergEyes contact lens wear for keratoconus.
Fernandez-Velazquez FJ · Eye Contact Lens · 2011Case Reports
Other devices of this type
Also filed under product code HQD.
- Menicon Sf-P (Tm)Menicon Co, Ltd. · PMA 2000
- OPTIMUM GP (roflufocon D, roflurocon E) Daily Wear Contact LensContamac, Ltd. · 510(k) 2018
- Rigid Gas Permeable Contact Lens SolutionPolymer Technology Corp. · 510(k) 2001
- Acuity 200 (fluoroxyfocon A) Rigid Gas Permeable Contact LensAcuity Polymers, Inc. · 510(k) 2024
- Visionary Optics Scleral Contact Lens (roflufocon D, roflufocon E, hexafocon A, hexafocon B, tisilfocon A, fluoroxyfocon A)Visionary Optics, LLC · 510(k) 2024
- Custom Stable Rigid Gas Permeable Scleral Contact LensValley Contax, Inc. · 510(k) 2022
- Acuity 18 (enflufocon A) Rigid Gas Permeable Contact LensAcuity Polymers, Inc. · 510(k) 2018
- FluoroPerm 30 & Paragon Thin (paflufocon C) RGP contact lenses with Tangible Hydra-PEGParagon Vision Sciences · 510(k) 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.